Here, we found MYO19, a mitochondrially localized myosin, was significantly overexpressed in LUSC and associated with poor prognosis, advanced tumor stages and reduced immune infiltration, suggesting that MYO19 has a certain diagnostic and prognosis value of LUSC treatment (22). This evidence concerns the gene MYH14 and neoplasm.